This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Beat the Market the Zacks Way: Credo, Palantir, Oracle in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 556.2% upside potential for Silence Therapeutics (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Silence Therapeutics (SLN) points to a 590.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Silence Therapeutics (SLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels
by Zacks Equity Research
Silence Therapeutics stock falls despite lowering lipoprotein levels in a phase II study of zerlasiran likely due to concerns regarding its competitive profile.
Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last?
by Zacks Equity Research
Silence Therapeutics (SLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
MediWound (MDWD) Moves 7.1% Higher: Will This Strength Last?
by Zacks Equity Research
MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Silence Therapeutics PLC Sponsored ADR (SLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Strength Seen in Silence Therapeutics PLC Sponsored ADR (SLN): Can Its 15.4% Jump Turn into More Strength?
by Zacks Equity Research
Silence Therapeutics PLC Sponsored ADR (SLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
All You Need to Know About Silence Therapeutics PLC Sponsored ADR (SLN) Rating Upgrade to Strong Buy
by Zacks Equity Research
Silence Therapeutics PLC Sponsored ADR (SLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Silence Therapeutics PLC Sponsored ADR (SLN) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Silence Therapeutics PLC Sponsored ADR (SLN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Here's Why Momentum in Silence Therapeutics PLC Sponsored ADR (SLN) Should Keep going
by Zacks Equity Research
Silence Therapeutics PLC Sponsored ADR (SLN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Does Silence Therapeutics PLC Sponsored ADR (SLN) Have the Potential to Rally 187.05% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at an 187.1% upside potential for Silence Therapeutics PLC Sponsored ADR (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Predict a 361.54% Upside in Silence Therapeutics PLC Sponsored ADR (SLN): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 361.5% upside potential for Silence Therapeutics PLC Sponsored ADR (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
BioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
BioCryst (BCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
New Strong Sell Stocks for May 9th
by Zacks Equity Research
ARCB, MRVL and SLN have been added to the Zacks Rank #5 (Strong Sell) List on May 9, 2023.
Silence Therapeutics PLC Sponsored ADR (SLN) Stock Jumps 9.3%: Will It Continue to Soar?
by Zacks Equity Research
Silence Therapeutics PLC Sponsored ADR (SLN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics
by Zacks Equity Research
Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics are part of the Zacks Industry Outlook article.
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
by Kinjel Shah
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.
Silence Therapeutics PLC Sponsored ADR (SLN) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Silence Therapeutics PLC Sponsored ADR (SLN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.